Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 1991Website:
http://www.vrtx.comNext earnings report:
05 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 32 min agoDividend
Analysts recommendations
Institutional Ownership
VRTX Latest News
Do you have $500? Here's one biotech stock you should consider buying and keeping for the long term.
Biotech company Vertex Pharmaceuticals (VRTX) has faced challenges in the stock market recently, affecting its 10% gain for the year. After a 5.6% increase following its earnings report earlier this month, the stock has lost that momentum and is now at its lowest point since June.
Lately, users of Zacks.com have been focusing on Vertex (VRTX). This interest prompts a closer look at what the stock might offer.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will participate in the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 9:00 AM ET. The company will be represented by Dr. Reshma Kewalramani, who is the President and CEO. Debjit Chattopadhyay from Guggenheim Partners will host the event and welcome Dr. Kewalramani.
Regulators are examining a drug that has the potential to be worth billions of dollars.
Vertex Pharmaceuticals (VRTX) has hit an important support level, making it an attractive option for investors based on technical analysis. The stock recently surpassed the 20-day moving average, indicating a positive trend in the short term.
From a technical viewpoint, Vertex Pharmaceuticals (VRTX) appears to be an appealing choice since it has just hit an important support level. VRTX has recently surpassed the 50-day moving average, indicating a positive trend in the short term.
The main figures for Vertex (VRTX) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be helpful to look at some of its important metrics in relation to Wall Street predictions and last year's results.
Vertex Pharmaceuticals (VRTX) finished the most recent trading session at $476.37, which is a decrease of 0.28% compared to the previous day.
This stock may not stay below $500 for much longer.
What type of business is Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of drug therapies for cystic fibrosis (CF) and other serious diseases. It was founded in 1989. Currently, the company's product portfolio includes medications such as SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. These three drugs combined are approved for the treatment of approximately half of the 75,000 CF patients in North America, Europe, and Australia.
What sector is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is in the Healthcare sector
What industry is Vertex Pharmaceuticals Incorporated in?
Vertex Pharmaceuticals Incorporated is in the Biotechnology industry
What country is Vertex Pharmaceuticals Incorporated from?
Vertex Pharmaceuticals Incorporated is headquartered in United States
When did Vertex Pharmaceuticals Incorporated go public?
Vertex Pharmaceuticals Incorporated initial public offering (IPO) was on 24 July 1991
What is Vertex Pharmaceuticals Incorporated website?
https://www.vrtx.com
Is Vertex Pharmaceuticals Incorporated in the S&P 500?
Yes, Vertex Pharmaceuticals Incorporated is included in the S&P 500 index
Is Vertex Pharmaceuticals Incorporated in the NASDAQ 100?
Yes, Vertex Pharmaceuticals Incorporated is included in the NASDAQ 100 index
Is Vertex Pharmaceuticals Incorporated in the Dow Jones?
No, Vertex Pharmaceuticals Incorporated is not included in the Dow Jones index
When was Vertex Pharmaceuticals Incorporated the previous earnings report?
No data
When does Vertex Pharmaceuticals Incorporated earnings report?
The next expected earnings date for Vertex Pharmaceuticals Incorporated is 05 February 2025